The Specific Role of CCL8 Chemokine in Atherosclerosis

Yulduz Yusupbaevna Baltaeva, Мoxigul Тurdialievna Yuldasheva, Мatlyuba Satvaldievna Palvanova, Mansurjon Safaralievich Hoshimov


Atherosclerosis is a chronic inflammatory disease that represents the primary cause of heart disease and stroke. C-C motif chemokine ligand 8 (CCL8) has been found in many diseases’ pathogenesis. Nevertheless, its molecular mechanism in atherosclerosis (AS) remains to be elucidated. Human microvascular endothelial cells (HMEcs) were stimulated by IFNα, IFNγand LPS, to establish experimental atherosclerosis. Recruitment of blood leukocytes to the injured vascular endothelium characterizes the initiation and progression of atherosclerosis and involves many inflammatory mediators, modulated by cells of both innate and adaptive immunity. The pro-inflammatory cytokine, interferon (IFN)-γ derived from T cells, is vital for both innate and adaptive immunity and is also expressed at high levels in atherosclerotic lesions. As such, IFN-γ plays a crucial role in the pathology of atherosclerosis through activation of signal transducer and activator of transcription (STAT)1. Our study indeed provides evidence that in HMECs STAT1 coordinates a platform for cross-talk between IFNγ and TLR4, and identifies a STAT1-dependent gene signature that reflects a pro-atherogenic state in coronary artery disease (CAD) and carotid atherosclerosis. Taken together, our data indicate that in the presence of appropriate stimuli, HMECs are highly responsive and consistently express CCL8.  However, upregulation of CCL8 led to suggest CCL8 could be an atherosclerosis therapeutic target. HMECs may therefore provide a better model for in vitro studies of atherosclerosis.


Atherosclerosis; Chemokines; Vulnerable Plaque; Biomarkers; CCL8; IFNγ; LPS; HMECs

Full Text:



Ades EW, Candal FJ, Swerlick RA, George VG, Summers S, Bosse DC, et al. (1992). HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J Invest Dermatol. Dec;99(6):683-90. doi: 10.1111/1523-1747.ep12613748.

Alain Tedgui, ZiadMallat. (2006). Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev. Apr;86(2):515-81. doi: 10.1152/physrev.00024.2005.

Antonelli A, Fallahi P, DelleSedie A, Ferrari SM, Maccheroni M, Bombardieri S, et al. (2008). High values of alpha (CXCL10) and beta (CCL2) circulating chemokines in patients with psoriatic arthritis, in presence or absence of autoimmune thyroiditis. Autoimmunity 41:537–42. doi: 10.1080/08916930802170401.

D. Luster, J. C. Unkeless, and J. V. Ravetch. (1985). “γ –Interferon transcriptionally regulates an early-response gene containing homology to platelet proteins,” Nature, vol. 315, no. 6021, pp. 672–676.

Fernandez E. J. and LolisE. (2002). “Structure, function, and inhibition of chemokines,” Annual Review of Pharmacology and Toxicology, vol. 42, pp. 469–499.

Groom J. R. and. Luster, A. D. (2011). “CXCR3 ligands: redundant, collaborative and antagonistic functions,” Immunology and Cell Biology, vol. 89, no. 2, pp. 207–215.

Hans A. R. Bluyssen, et al. (2011). STAT1 as a novel therapeutical target in pro-atherogenic signal integration of IFNγ, TLR4 and IL-6 in vascular disease. Cytokine Growth Factor Rev. Aug;22(4):211-9. doi: 10.1016/j.cytogfr.2011.06.003.

Hans A. R. Bluyssen, et al. (2012). STAT1 as a central mediator of IFN γ and TLR4 Signal integration in vascular dysfunction. JAKSTAT. Oct 1; 1(4): 241–249. doi: 10.4161/jkst.22469***

Hans A. R. Bluyssen, et al. (2014). STAT1-dependent signal integration between IFNgamma and TLR4 in vascular cells reflect pro-atherogenic responses in human atherosclerosis. PloS one. 9:e113318. Published online 2014 Dec 5. doi: 10.1371/journal.pone.0113318.

Hans A. R. Bluyssen, et al. (2018). A Positive Feedback Amplifier Circuit That Regulates Interferon (IFN)-Stimulated Gene Expression and Controls Type I and Type II IFN Responses. Front Immunol. May 8;9:1135. doi: 10.3389/fimmu.2018.01135. eCollection 2018.

Hansson GK, Libby P. (2006). The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol; 6:508-19;

Haverkate F, Thompson SG, Pyke SD, et al. (1997). Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet. 349:462–466.

Hughes C.E., Nibbs R.J.B. (2018). A guide to chemokines and their receptors. FEBS J. 285:2944–2971. doi: 10.1111/febs.14466.

Kraaijeveld AO, de Jager SC, van Berkel TJ, Biessen EA, Jukema JW. (2007). Chemokines and atherosclerotic plaque progression: towards therapeutic targeting? Curr Pharm Des. 13(10):1039-52. doi: 10.2174/138161207780487584.

Lin J, Kakkar V, Lu X. (2014). Impact of MCP-1 in atherosclerosis. Curr Pharm Des. 20(28):4580-8. doi: 10.2174/1381612820666140522115801.

Mohty AM, Grob JJ, Mohty M, Richard MA, Olive D, Gaugler B. (2010). Induction of IP-10/CXCL10 secretion as an immunomodulatory effect of low-dose adjuvant interferon-alpha during treatment of melanoma. Immunobiology 215:113–23. doi: 10.1016/j.imbio.2009.03.008.

P.Libby, Paul M. Ridker, et al. (2002). Inflammation and atherosclerosis. Circulation. Mar 5;105(9):1135-43. doi: 10.1161/hc0902.104353.

Pleunie van den Borne, et al. (2014). The Multifaceted Functions of CXCL10 in Cardiovascular Disease. Biomed Res Int. 2014:893106. doi: 10.1155/2014/893106. Epub 2014 Apr 23.

Pohjanvirta T et al. (2006). Evaluation of various housekeeping genes for their applicability for normalization of mRNA expression in dioxin-treated rats.ChemBiol Interact. Mar 25;160(2):134-49. doi: 10.1016/j.cbi.2006.01.001. Epub 2006 Feb 8.

Ridiandries A, Tan JT, Bursill CA. (2016). The Role of CC-Chemokines in the Regulation of Angiogenesis. Int J Mol Sci. Nov 8; 17(11):1856. doi: 10.3390/ijms17111856.

Ridker PM, Hennekens CH, Buring JE, et al. (2000). C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 342:836–843.

Shehadeh N, Pollack S, Wildbaum G, Zohar Y, Shafat I, Makhoul R, et al. (2009). Selective autoantibody production against CCL3 is associated with human type 1 diabetes mellitus and serves as a novel biomarker for its diagnosis. J Immunol. 182:8104–9. doi: 10.4049/jimmunol.0803348.

Sikorski K, Hans A R Bluyssen et al. (2011). STAT1-mediated signal integration between IFNgamma and LPS leads to increased EC and SMC activation and monocyte adhesion. Am J Physiol Cell Physiol. Jun;300(6):C1337-44. doi: 10.1152/ajpcell.00276.2010. Epub 2011 Feb 23.

Silencing CCL8 inhibited the proliferation and migration of PDGF-BB-stimulated human aortic smooth muscle cells. Shipeng Dai, Jiangang Zhang, Zesheng Xu. BiosciBiotechnolBiochem. 2020 Aug; 84(8):1585-1593. doi: 10.1080/09168451.2020.1762160.

Struyf S, Proost P, Vandercappellen J, Dempe S, Noyens B, Nelissen S, Gouwy M, Locati M, Opdenakker G, Dinsart C, Van DammeJ. (2009). Synergistic up-regulation of MCP-2/CCL8 activity is counteracted by chemokine cleavage, limiting its inflammatory and anti-tumoral effects. Eur J Immunol. Mar; 39(3):843-57. doi: 10.1002/eji.200838660.

TaubD. D. (1996). “Chemokine-leukocyte interactions. The voodoo that they do so well,” Cytokine & Growth Factor Reviews, vol. 7, no. 4, pp. 355–376.

Wang Z, Han J, Cui Y, Zhou X, Fan K. (2013). miRNA-21 inhibition enhances RANTES and IP-10 release in MCF-7 via PIAS3 and STAT3 signalling and causes increased lymphocyte migration. BiochemBiophys Res Commun. 439:384–9. doi: 10.1016/j.bbrc.2013.08.072.

Zlotnik A., Yoshie O. (2000). Chemokines: A new classification system and their role in immunity. Immunity. 12:121–127. doi: 10.1016/S1074-7613(00)80165-X.



  • There are currently no refbacks.

Copyright (c) 2021 International Journal of Multicultural and Multireligious Understanding

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

International Journal of Multicultural and Multireligious Understanding (IJMMU) ISSN 2364-5369
Copyright © 2014-2018 IJMMU. All rights reserved.